Poster 1023: Dupilumab suppresses Th2 inflammation in adult asthma and atopic dermatitis

Methods The clinical trial design and results in adult patients were previously reported for asthma (NEJM 2013;368:2455) and AD (JID 2013;133:S177-S178). In the asthma study, inhaled glucocorticoids and long-acting beta-agonist were withdrawn after week 4 [W4] of 12 weeks of qw DPL [300 mg] or placebo [PBO]. Asthma exacerbation occurrence was the primary endpoint. Fractional exhaled nitric oxide (FeNO) and blood eotaxin-3, TARC and IgE were measured as pharmacodynamic markers. Two AD studies in adults with moderate-to-severe AD evaluated DPL (75, 150, 300 mg) or PBO qw for 4 weeks on itch (5D pruritus questionnaire), Eczema Area and Severity Index (EASI), TARC and total IgE.